Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer

Immune checkpoint inhibitors (ICIs), a type of immunotherapy, have become one of the most important therapeutic options for first- and second-line treatment of advanced non-small cell lung cancer (NSCLC). Recent clinical studies have shown that immunotherapy can offer substantial survival benefits t...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Hanfei, Li, Wenqian, Qian, Lei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181868/
https://www.ncbi.nlm.nih.gov/pubmed/34158740
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.02.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8181868/
https://www.ncbi.nlm.nih.gov/pubmed/34158740
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.02.08

Ejemplares similares